Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ross Products sales

This article was originally published in The Tan Sheet

Executive Summary

Abbott Labs' U.S. nutritional sales fall 1.9% to $579 mil. in Q1, driven by double-digit decline in pediatric nutritionals. Similac infant formula maker says pediatric sales "continued to be impacted by heavy competitive spending." Ross has increased promotional spending, which "is yielding positive results, and we're beginning to see the results of a turnaround in our non-WIC share, which has been under pressure in recent quarters," Divisional VP-Investor Relations John Thomas tells analysts during April 9 call. Launch of DHA/ARA-fortified Similac Advance, other marketing actions expected to drive second-half growth. Abbott's Q1 consolidated sales were $4.19 bil., up 17.7% from year-ago quarter, with net earnings of $854.3 mil., up 16.2% excluding one-time charges in 2001...

You may also be interested in...

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Covid-19 Scam Complaints Double In A Week, But FTC Enforcement Considers 'Good Faith' Factor

FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.

No Facility Inspections? No Shortage Of Bogus Pandemic Claims Found Online By US Agencies

Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts